BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $6,197,187 | -17.9% | 235,009 | -46.4% | 0.02% | -10.0% |
Q2 2023 | $7,544,832 | +59.6% | 438,653 | +53.9% | 0.02% | +33.3% |
Q1 2023 | $4,726,875 | +538268.5% | 285,095 | +146.8% | 0.02% | +275.0% |
Q4 2022 | $878 | -99.9% | 115,537 | -29.1% | 0.00% | -42.9% |
Q3 2022 | $1,619,000 | -44.4% | 162,880 | -44.6% | 0.01% | +40.0% |
Q2 2022 | $2,912,000 | +71.9% | 293,970 | +88.7% | 0.01% | 0.0% |
Q1 2022 | $1,694,000 | -55.2% | 155,811 | -31.3% | 0.01% | -50.0% |
Q4 2021 | $3,785,000 | -64.8% | 226,857 | +0.8% | 0.01% | -63.0% |
Q3 2021 | $10,746,000 | -21.1% | 224,979 | +0.7% | 0.03% | -22.9% |
Q2 2021 | $13,616,000 | -0.8% | 223,463 | +0.1% | 0.04% | +12.9% |
Q1 2021 | $13,729,000 | +4357.5% | 223,214 | +5055.1% | 0.03% | +3000.0% |
Q4 2020 | $308,000 | -40.1% | 4,330 | -68.4% | 0.00% | 0.0% |
Q3 2020 | $514,000 | – | 13,698 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |